

Capstone Therapeutics Corp.  
Form 8-K  
December 06, 2012

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 OR 15(d) of  
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) **December 6, 2012**

**CAPSTONE THERAPEUTICS CORP.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**000-21214**  
(Commission File Number)

**86-0585310**  
(IRS Employer  
Identification No.)

**1275 West Washington Street, Suite 101, Tempe, Arizona**  
(Address of principal executive offices)

**85281**  
(Zip Code)

**(602) 286-5520**  
Registrant's telephone number, including area code

---

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Section 8 - Other Events**

**Item 8.01. Other Events.**

On December 6, 2012, Capstone Therapeutics Corp. issued a press release announcing that LipimetiX Development, LLC ("LipimetiX") has received notice from the US Food and Drug Administration that Apolipoprotein E Mimetic Peptide AEM-28 has been granted Orphan Drug Designation for the treatment of Homozygous Familial Hypercholesterolemia. The Company entered into the LipimetiX joint venture with LipimiteX LLC in August 2012. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 8.01 of this Form 8-K and Exhibit 99.1 furnished herewith shall not be deemed "filed" for

purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in any such filing.

**Section 9 - Financial Statements and Exhibits**

**Item 9.01. Financial Statements and Exhibits.**

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
99.1	Press Release dated December 6, 2012

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CAPSTONE THERAPEUTICS CORP.**

Date: December 6, 2012

**/s/ JOHN M. HOLLIMAN, III**  
John M. Holliman, III  
*Executive Chairman*